stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Revenue
CRISPR Therapeutics AG's revenue for fiscal 2025 was $3.5M, down 90.6% from $37.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $25.2M. Over the past ten years it has ranged from $247.0K (fiscal 2015) to $915.0M (fiscal 2021); the current reading is higher than 45% of that period. CRISPR Therapeutics AG ranks 173rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.5M | (90.59%) |
| FY2024 | $37.3M | (89.95%) |
| FY2023 | $371.2M | 30,885.48% |
| FY2022 | $1.2M | (99.87%) |
| FY2021 | $915.0M | 127,154.94% |
| FY2020 | $719.0K | (99.75%) |
| FY2019 | $289.6M | 9,169.85% |
| FY2018 | $3.1M | (92.38%) |
| FY2017 | $41.0M | 693.90% |
| FY2016 | $5.2M | 1,990.69% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $12.7M | 24.44% |
| Jun 2026 | $10.2M | 598.29% |
| Mar 2026 | $1.5M | 68.75% |
| Dec 2025 | $864.0K | (2.81%) |
| 38 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | $1.3B |
| TVTX Travere Therapeutics, Inc. compare | $651.0M |
| CRSP CRISPR Therapeutics AG | $25.2M |
| COGT Cogent Biosciences, Inc. compare | $23.2M |
| DNTH Dianthus Therapeutics, Inc. compare | $2.7M |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CRSP
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement